SITC 2024
Category: Press release
Transgene Reports Business, Pipeline and Financial Update for Q3 2024
Financial Q3 2024
Transgene and ProBioGen Join Forces to Advance Individualized Cancer Vaccine Develpment
ProBioGen
Transgene Provides Update on Phase II Trial of Therapeutic Cancer Vaccine TG4001 in Recurrent or Metastatic HPV16-Positive Cervical and Anogenital Cancers
TG4001 2024
Transgene to Present a Poster on Updated Data for TG4050 at SITC 2024
SITC 2024
Transgene to Report Major Clinical Data before the end of 2024 – Confirmed Financial Visibility until Q4 2025
H1 2024 FINANCIAL RESULTS
Transgene and BioInvent’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatment
BT-001 ESMO
Transgene Appoints Two Seasoned Leaders in Oncology to Drive its Next Phase of Innovation
Nominations
Transgene and BioInvent to Present Promising Initial Phase I/IIa Data on Oncolytic Virus, BT-001, at ESMO 2024
ESMO ABSTRACT
Transgene to Participate in HTID Conference and Investor Access Forum in Paris
investor events
